ABMD - Abbott suspends study comparing HeartMate PHP against Abiomed's Impella

According to an update posted on the federal register for clinical trials, Abbott ([[ABT]] +0.2%) has suspended the recruitment for SHIELD II clinical trial citing reports of ‘decreased impeller speed at the end of a procedure.’The randomized trial targeting to enroll 716 participants compared Abbott’s HeartMate PHP catheter with any of Impella pumps of Abiomed ([[ABMD]] +1.0%) for use in high-risk percutaneous coronary intervention (“PCI”).In late 2019, Abiomed rose when the trial’s expected completion date was pushed back to December 2021.

For further details see:

Abbott suspends study comparing HeartMate PHP against Abiomed's Impella